Title |
Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2)
|
---|---|
Published in |
Journal of Translational Medicine, October 2012
|
DOI | 10.1186/1479-5876-10-216 |
Pubmed ID | |
Authors |
Yi-Che Changchien, Péter Tátrai, Gergő Papp, Johanna Sápi, László Fónyad, Miklós Szendrői, Zsuzsanna Pápai, Zoltán Sápi |
Abstract |
Enhancer of zeste homologue 2 (EZH2) is a polycomb group (PcG) family protein. Acting as a histone methyltransferase it plays crucial roles in maintaining epigenetic stem cell signature, while its deregulation leads to tumor development. EZH2 overexpression is commonly associated with poor prognosis in a variety of tumor types including carcinomas, lymphomas and soft tissue sarcomas. However, although the synovial sarcoma fusion proteins SYT-SSX1/2/4 are known to interact with PcG members, the diagnostic and prognostic significance of EZH2 expression in synovial sarcoma has not yet been investigated. Also, literature data are equivocal on the correlation between EZH2 expression and the abundance of trimethylated histone 3 lysine 27 (H3K27me3) motifs in tumors. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 19 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 4 | 21% |
Student > Postgraduate | 3 | 16% |
Researcher | 3 | 16% |
Professor | 2 | 11% |
Other | 2 | 11% |
Other | 3 | 16% |
Unknown | 2 | 11% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 8 | 42% |
Biochemistry, Genetics and Molecular Biology | 3 | 16% |
Immunology and Microbiology | 1 | 5% |
Agricultural and Biological Sciences | 1 | 5% |
Psychology | 1 | 5% |
Other | 1 | 5% |
Unknown | 4 | 21% |